nifedipine has been researched along with Disease Models, Animal in 217 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mice were infused with β-aminopropionitrile for 2 weeks and angiotensin II for 6 weeks to induce aortic aneurysm formation." | 7.88 | Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation. ( Chuma, M; Fujino, H; Fukushima, K; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kohara, Y; Sairyo, E; Sakurada, T; Takechi, K; Tamaki, T; Tsuchiya, K; Yoshizumi, M; Zamami, Y, 2018) |
| "Nifedipine-induced gingival overgrowth (NIGO) is characterized by cell proliferation and extracellular matrix (ECM) component accumulation in gingival connective tissues, with varying degrees of inflammation and fibrosis." | 7.81 | Local Inflammation Alters MMP-2 and MMP-9 Gelatinase Expression Associated with the Severity of Nifedipine-Induced Gingival Overgrowth: a Rat Model Study. ( Chen, LJ; Li, WL; Tang, M; Wu, CH; Yang, J; Zhao, SL, 2015) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 7.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 7.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| " The purpose of the present study was to evaluate the effects of nifedipine, a calcium channel blocker, on epileptic seizures and on reperfusion arrhythmias in rats prone to audiogenic epileptic seizures (Wistar audiogenic rats, WAR) and in normal Wistar rats (N = 6/group)." | 7.78 | Anticonvulsant and antiarrhythmic effects of nifedipine in rats prone to audiogenic seizures. ( Almeida, AP; Damasceno, DD; Doretto, MC; Ferreira, AJ, 2012) |
| "To investigate a possible relation between hypercholesterolemia and detrusor smooth muscle function, we studied the contractile response to potassium challenge, carbachol (CCh), and the components of CCh-induced contractile mechanism in high-cholesterol diet-fed rats." | 7.78 | The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels. ( Balkanci, ZD; Bayrak, S; Erdem, A; Karabulut, I; Karaismailoğlu, S; Pehlivanoğlu, B, 2012) |
| " PAR(2) and bradykinin subtype 2 receptor (B(2)) expression and function were assessed in relation to hypertensive encephalopathy (HE) and cerebral hemorrhage (CH) in middle cerebral arteries (MCA) of Kyoto Wistar stroke-prone spontaneously hypertensive rats (SHRsp)." | 7.76 | Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats. ( Daneshtalab, N; McGuire, JJ; Smeda, JS, 2010) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 7.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| " The aim of the present study was to examine whether the CCBs nilvadipine and diltiazem reduce ocular inflammation in endotoxin-induced uveitis (EIU)." | 7.76 | Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. ( Ishida, S; Koto, T; Nagai, N; Oike, Y, 2010) |
| " The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH)." | 7.75 | CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. ( Cheng, YS; Cui, B; Dai, DZ; Dai, Y; Li, N; Zhang, TT, 2009) |
| "The aim of study is to investigate the effect of nifedipine on viral myocarditis in an animal model." | 7.75 | Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. ( Hu, D; Liu, W; Matsumori, A; Shimada, M; Xiao, J, 2009) |
| "To investigate the effect of nilvadipine, a calcium channel blocker, upon the retina of retinal degeneration slow (rds) mouse, nilvadipine was intraperitoneally injected into heterozygous rds mice for up to 200 days." | 7.74 | Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse. ( Mizukoshi, S; Nakazawa, M; Takeuchi, K, 2008) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 7.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Topiramate (TPM), a new generation antiepileptic drug was investigated for its anticonvulsant effects in various models of genetically determined and chemically induced epilepsy in rodents." | 7.72 | Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. ( Citraro, R; Constanti, A; De Sarro, G; Ferreri, G; Russo, E, 2004) |
| "Acute hemodynamic effects of beraprost sodium were tested in a canine vasoconstrictive pulmonary hypertension model induced by the continuous infusion of U-46619, a thromboxane A(2)mimetic." | 7.71 | Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. ( Kurumatani, H; Matsushita, T; Tamura, M, 2001) |
| "Nifedipine (NIF) may aggravate cyclosporin A (CsA)-induced gingival overgrowth because the potentiated gingival overgrowth has been observed in the patients treated with CsA and NIF." | 7.71 | Does nifedipine aggravate cyclosporin--induced gingival overgrowth? An experiment in rats. ( Chiang, CY; Chiu, HC; Fu, E; Liu, D, 2001) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 7.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "A new model of acute lung injury was established by administering oleic acid into superior vena cava in experimental rat during acute hypoxia, which was formed by putting the animal in a hypobaric room, and reduced the pressure gradually in uniform speed till a simulated environment of 6000 m above sea level was formed and lasted for 12 hours." | 7.70 | [Experimental study on effect of altitude xishi capsule in treating oleic acid induced lung injury in acute hypoxia rats]. ( Cui, S; Guo, X, 1998) |
| "The aim of the study was to determine if pretreatment with misoprostol (a prostaglandin analogue) or nifedipine (a calcium antagonist), know protectants of the whole liver, would ameliorate the ischemia-reperfusion injury (IRI) of resected liver associated with vascular occlusion." | 7.69 | Hepatic ischemia-reperfusion injury modification during liver surgery in rats: pretreatment with nifedipine or misoprostol. ( Hardy, KJ; Shulkes, A; Tancheroen, S, 1995) |
| "Cardiovascular responses to the calcium antagonist nifedipine, alone and combined with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of endotoxin-induced pulmonary hypertension." | 7.67 | The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet. ( Huth, RG; Jüngst, BK; Schranz, D; Stopfkuchen, H, 1988) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 7.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| "In the asthmatic model mainly mediated by the endogenous slow reacting substance of anaphylaxis (SRS-A) induced by the antigen inhalation to passively sensitized guinea pigs, continuous intravenous infusion of nifedipine (Adalat) at a speed of 7 micrograms/kg/min depressed the airway open pressure by about 68% compared to the saline-treated group and produced a delay in the time to peak response." | 7.67 | Effect of a Ca2+ antagonist, nifedipine, on the experimental asthma mediated mainly by slow reacting substance of anaphylaxis. ( Fujimura, M; Ishizaki, T; Kanamori, K; Koshino, T; Matsuda, T; Minami, S; Miyabo, S; Nishioka, S; Okafuji, K; Saga, T, 1985) |
| "Periodontitis was induced by oral inoculation with Porphyromonas gingivalis over a 3-week time period." | 5.91 | Nifedipine attenuates alveolar bone destruction and improves trabecular microarchitectures in mice with experimental periodontitis. ( Choi, EY; Choi, IS; Kim, SJ; Lee, AR; Lee, JE; Lee, Y, 2023) |
| "Aortic aneurysms are prevalent and severe vascular diseases with high mortality from unpredicted ruptures, while the only treatment option is surgical correction of large aneurysms with considerable risk." | 5.72 | Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication. ( Cai, H; Huang, K; Wu, Y; Youn, JY; Zhang, Y, 2022) |
| " The current investigations clarified the efficiency of this novel and unique NF loaded in situ gel for the control of the IOP compared to the conventional ophthalmic dosage forms." | 5.62 | Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment. ( Ahmed, KA; El-Feky, YA; El-Telbany, DFA; El-Telbany, RFA; Fares, AR; Zayed, G, 2021) |
| "Nifedipine toxicity was characterized by vasodilatory hypotension, impaired vascular contractility, and tachycardia with terminal bradycardia." | 5.43 | Pilot Trial of Intravenous Lipid Emulsion Treatment for Severe Nifedipine-Induced Shock. ( Beuhler, MC; Kerns, WP; Murphy, CM; Nicholson, B; Quinn, ME; Shoe, T; Williams, C, 2016) |
| "Nifedipine alone was not sufficient to promote gingival enlargement or periodontal destruction in the absence of the ligature." | 5.36 | Effect of nifedipine on gingival enlargement and periodontal breakdown in ligature-induced periodontitis in rats. ( Fernandes, MI; Gaio, EJ; Oppermann, RV; Rados, PV; Rösing, CK; Susin, C, 2010) |
| " In both age groups, chronic nifedipine administration reduced neurogenic contractions of isolated superior mesenteric artery, but did not significantly affect the dose-response curve to exogenous noradrenaline in 8-week-old rats." | 5.35 | Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. ( Török, J; Zemančíková, A, 2009) |
| "Treatment with nifedipine resulted in a significant inhibition of the progression of AAA such as aneurismal dilation at 14 and 28 days compared to the control (week 2: control, 2." | 5.35 | Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. ( Izawa, K; Kunugiza, Y; Morishita, R; Ogihara, T; Osako, MK; Tomita, N; Yamasaki, K, 2008) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 5.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 5.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| "Nitrendipine proved to be a potent hypotensive agent in sham shock cats when infused over a 4 h period (156 +/- 9 to 90 +/- 5 mm Hg) (P less than 0." | 5.27 | Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock. ( Hock, CE; Lefer, AM; Su, JY, 1984) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 5.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| "So the objective of the present work was to formulate an advanced drug delivery system in the form of bio-responsive microneedles by incorporating nifedipine, a cardiodepressant and diltiazem, a vasodilator for effective synergism in the treatment of hypertension." | 3.96 | Engineering of Nanospheres Dispersed Microneedle System for Antihypertensive Action. ( Sardesai, M; Shende, P, 2020) |
| "BackgroundIn the clinical setting, verapamil is contraindicated in neonates and infants, because of the perceived risk of hypotension or bradyarrhythmia." | 3.88 | Postnatal developmental changes in the sensitivity of L-type Ca ( Ding, WG; Hoshino, S; Maruo, Y; Matsuura, H; Nakagawa, M; Omatsu-Kanbe, M; Sagawa, H; Yoshioka, K, 2018) |
| "The mice were infused with β-aminopropionitrile for 2 weeks and angiotensin II for 6 weeks to induce aortic aneurysm formation." | 3.88 | Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation. ( Chuma, M; Fujino, H; Fukushima, K; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kohara, Y; Sairyo, E; Sakurada, T; Takechi, K; Tamaki, T; Tsuchiya, K; Yoshizumi, M; Zamami, Y, 2018) |
| "Nifedipine-induced gingival overgrowth (NIGO) is characterized by cell proliferation and extracellular matrix (ECM) component accumulation in gingival connective tissues, with varying degrees of inflammation and fibrosis." | 3.81 | Local Inflammation Alters MMP-2 and MMP-9 Gelatinase Expression Associated with the Severity of Nifedipine-Induced Gingival Overgrowth: a Rat Model Study. ( Chen, LJ; Li, WL; Tang, M; Wu, CH; Yang, J; Zhao, SL, 2015) |
| "As hypertension (HT) is one of the risk factors for lower urinary tract symptoms, we investigated the effect of an angiotensin II type I receptor blocker, olmesartan, on bladder dysfunction in the spontaneously hypertensive rat (SHR)." | 3.80 | Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress. ( Dimitriadis, F; Kinoshita, Y; Martin, DT; Ohmasa, F; Oikawa, R; Oiwa, H; Saito, M; Satoh, I; Shimizu, S; Tomita, S; Tsounapi, P, 2014) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 3.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| "We have studied the prophylactic administration of nifedipine and its molecular mechanism involved in reducing the transvascular leakage and inflammation in rats under hypoxia." | 3.78 | Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. ( M, C; Mathew, T; P, H; S K S, S; S, S, 2012) |
| " The purpose of the present study was to evaluate the effects of nifedipine, a calcium channel blocker, on epileptic seizures and on reperfusion arrhythmias in rats prone to audiogenic epileptic seizures (Wistar audiogenic rats, WAR) and in normal Wistar rats (N = 6/group)." | 3.78 | Anticonvulsant and antiarrhythmic effects of nifedipine in rats prone to audiogenic seizures. ( Almeida, AP; Damasceno, DD; Doretto, MC; Ferreira, AJ, 2012) |
| "To investigate a possible relation between hypercholesterolemia and detrusor smooth muscle function, we studied the contractile response to potassium challenge, carbachol (CCh), and the components of CCh-induced contractile mechanism in high-cholesterol diet-fed rats." | 3.78 | The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels. ( Balkanci, ZD; Bayrak, S; Erdem, A; Karabulut, I; Karaismailoğlu, S; Pehlivanoğlu, B, 2012) |
| "These results suggest that nifedipine can enhance insulin sensitivity and reduce white adipose tissue, possibly related to stimulation of adipocyte differentiation." | 3.77 | Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. ( Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Nakaoka, H; Senba, I; Sone, H, 2011) |
| " PAR(2) and bradykinin subtype 2 receptor (B(2)) expression and function were assessed in relation to hypertensive encephalopathy (HE) and cerebral hemorrhage (CH) in middle cerebral arteries (MCA) of Kyoto Wistar stroke-prone spontaneously hypertensive rats (SHRsp)." | 3.76 | Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats. ( Daneshtalab, N; McGuire, JJ; Smeda, JS, 2010) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 3.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| " The aim of the present study was to examine whether the CCBs nilvadipine and diltiazem reduce ocular inflammation in endotoxin-induced uveitis (EIU)." | 3.76 | Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. ( Ishida, S; Koto, T; Nagai, N; Oike, Y, 2010) |
| " The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH)." | 3.75 | CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. ( Cheng, YS; Cui, B; Dai, DZ; Dai, Y; Li, N; Zhang, TT, 2009) |
| "The aim of study is to investigate the effect of nifedipine on viral myocarditis in an animal model." | 3.75 | Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. ( Hu, D; Liu, W; Matsumori, A; Shimada, M; Xiao, J, 2009) |
| "To investigate the effect of nilvadipine, a calcium channel blocker, upon the retina of retinal degeneration slow (rds) mouse, nilvadipine was intraperitoneally injected into heterozygous rds mice for up to 200 days." | 3.74 | Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse. ( Mizukoshi, S; Nakazawa, M; Takeuchi, K, 2008) |
| " Application of APV and nifedipine exacerbated low Mg(2+)-induced ILEs in the hippocampus but not the neocortex, indicating a distinct pharmacology for partial seizures of different brain regions." | 3.73 | Increased seizure susceptibility of the hippocampus compared with the neocortex of the immature mouse brain in vitro. ( Abdelmalik, PA; Burnham, WM; Carlen, PL, 2005) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 3.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "MCAs from srSHR and prestroke SHRSP exhibited pressure-dependent constriction and constricted in response to vasopressin or serotonin in the presence of nifedipine or the absence of [Ca2+]o." | 3.72 | Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction. ( Smeda, JS, 2003) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Topiramate (TPM), a new generation antiepileptic drug was investigated for its anticonvulsant effects in various models of genetically determined and chemically induced epilepsy in rodents." | 3.72 | Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. ( Citraro, R; Constanti, A; De Sarro, G; Ferreri, G; Russo, E, 2004) |
| "MCAs from DSS rats after stroke constricted in response to vasopressin but were unable to constrict in response to pressure or PDB in the presence of nifedipine, whereas those from DSS rats before stroke and from DSR rats constricted in response to all the stimuli." | 3.71 | Cerebrovascular alterations in pressure and protein kinase C-mediated constriction in Dahl salt-sensitive rats. ( Payne, GW; Smeda, JS, 2002) |
| "Acute hemodynamic effects of beraprost sodium were tested in a canine vasoconstrictive pulmonary hypertension model induced by the continuous infusion of U-46619, a thromboxane A(2)mimetic." | 3.71 | Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. ( Kurumatani, H; Matsushita, T; Tamura, M, 2001) |
| "Nifedipine (NIF) may aggravate cyclosporin A (CsA)-induced gingival overgrowth because the potentiated gingival overgrowth has been observed in the patients treated with CsA and NIF." | 3.71 | Does nifedipine aggravate cyclosporin--induced gingival overgrowth? An experiment in rats. ( Chiang, CY; Chiu, HC; Fu, E; Liu, D, 2001) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 3.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "The three treatments regressed cardiac hypertrophy and normalized sodium/hydrogen ion exchange exchange activity in SHR, and losartan was the most effective treatment for reversing cardiac hypertrophy, despite producing effects on blood pressure and sodium/hydrogen exchange activity similar to that of other antihypertensive drugs." | 3.71 | Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats. ( Alvarez, BV; Cingolani, HE; De Hurtado, MC; Ennis, IL, 2002) |
| "A new model of acute lung injury was established by administering oleic acid into superior vena cava in experimental rat during acute hypoxia, which was formed by putting the animal in a hypobaric room, and reduced the pressure gradually in uniform speed till a simulated environment of 6000 m above sea level was formed and lasted for 12 hours." | 3.70 | [Experimental study on effect of altitude xishi capsule in treating oleic acid induced lung injury in acute hypoxia rats]. ( Cui, S; Guo, X, 1998) |
| " The atherogenic significance of Ca ions and arterial Ca overload was examined under the influence of nicotine, oxidatively modified low-density lipoproteins, spontaneous hypertension, and an elevated extracellular Ca concentration or vitamin D3." | 3.69 | Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. ( Czirfuzs, A; Fleckenstein-Grün, G; Frey, M; Matyas, S; Thimm, F, 1994) |
| "The aim of the study was to determine if pretreatment with misoprostol (a prostaglandin analogue) or nifedipine (a calcium antagonist), know protectants of the whole liver, would ameliorate the ischemia-reperfusion injury (IRI) of resected liver associated with vascular occlusion." | 3.69 | Hepatic ischemia-reperfusion injury modification during liver surgery in rats: pretreatment with nifedipine or misoprostol. ( Hardy, KJ; Shulkes, A; Tancheroen, S, 1995) |
| " Angina pectoris was induced by methacholine or isoproterenol, and the change in the ST-segments in the electrocardiogram (ECG) was used as the parameter to indicate angina pectoris." | 3.68 | Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats. ( Fukata, Y; Fukushima, H; Harada, K; Kaneta, S; Miwa, A; Ogawa, N, 1993) |
| "Cardiovascular responses to the calcium antagonist nifedipine, alone and combined with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of endotoxin-induced pulmonary hypertension." | 3.67 | The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet. ( Huth, RG; Jüngst, BK; Schranz, D; Stopfkuchen, H, 1988) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 3.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| " The dihydropyridine agents, CRE-223 and Nifedipine, were highly protective against experimental thrombosis, whereas Verapamil had a weaker and much shorter effect and, on the other hand, Diltiazem had no protective effect over a range of doses." | 3.67 | The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice. ( Ortega, MP; Priego, JG; Statkow, PR; Sunkel, C, 1987) |
| "In the asthmatic model mainly mediated by the endogenous slow reacting substance of anaphylaxis (SRS-A) induced by the antigen inhalation to passively sensitized guinea pigs, continuous intravenous infusion of nifedipine (Adalat) at a speed of 7 micrograms/kg/min depressed the airway open pressure by about 68% compared to the saline-treated group and produced a delay in the time to peak response." | 3.67 | Effect of a Ca2+ antagonist, nifedipine, on the experimental asthma mediated mainly by slow reacting substance of anaphylaxis. ( Fujimura, M; Ishizaki, T; Kanamori, K; Koshino, T; Matsuda, T; Minami, S; Miyabo, S; Nishioka, S; Okafuji, K; Saga, T, 1985) |
| " Animals in each group daily received NIF in dimethyl sulfoxide by gastric feeding at a dosage of 0 (control), 30, or 50 mg/kg body weight for 9 weeks." | 2.40 | Nifedipine-induced gingival overgrowth in rats: brief review and experimental study. ( Fu, E; Hsiao, CT; Hsieh, YD; Nieh, S; Shen, EC; Wikesjö, UM, 1998) |
| "High-altitude pulmonary edema (HAPE) occurs in unacclimatized individuals who are rapidly exposed to altitudes in excess of 2450 m." | 2.39 | High-altitude pulmonary edema: current concepts. ( Hultgren, HN, 1996) |
| "Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed (anatomic area at risk)." | 2.37 | Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction. ( Jennings, RB; Reimer, KA, 1985) |
| "Periodontitis was induced by oral inoculation with Porphyromonas gingivalis over a 3-week time period." | 1.91 | Nifedipine attenuates alveolar bone destruction and improves trabecular microarchitectures in mice with experimental periodontitis. ( Choi, EY; Choi, IS; Kim, SJ; Lee, AR; Lee, JE; Lee, Y, 2023) |
| "Aortic aneurysms are prevalent and severe vascular diseases with high mortality from unpredicted ruptures, while the only treatment option is surgical correction of large aneurysms with considerable risk." | 1.72 | Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication. ( Cai, H; Huang, K; Wu, Y; Youn, JY; Zhang, Y, 2022) |
| " The current investigations clarified the efficiency of this novel and unique NF loaded in situ gel for the control of the IOP compared to the conventional ophthalmic dosage forms." | 1.62 | Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment. ( Ahmed, KA; El-Feky, YA; El-Telbany, DFA; El-Telbany, RFA; Fares, AR; Zayed, G, 2021) |
| "Cortical dysplasia is the most common etiology of intractable epilepsy." | 1.48 | Axon Initial Segment Structural Plasticity is Involved in Seizure Susceptibility in a Rat Model of Cortical Dysplasia. ( Feng, L; Wang, YL; Xiao, B; Yue, ZW, 2018) |
| "Nifedipine toxicity was characterized by vasodilatory hypotension, impaired vascular contractility, and tachycardia with terminal bradycardia." | 1.43 | Pilot Trial of Intravenous Lipid Emulsion Treatment for Severe Nifedipine-Induced Shock. ( Beuhler, MC; Kerns, WP; Murphy, CM; Nicholson, B; Quinn, ME; Shoe, T; Williams, C, 2016) |
| "Bladder function of db/db (type 2 diabetes) and wild type (Wt) mice was evaluated by behavioral tests and in vivo cystometry." | 1.40 | T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction. ( Chitaley, K; Jiang, X; Luttrell, I; Yang, CC, 2014) |
| "Treatment with rutin and quercetin ameliorated the effects of high salt diet on these biochemical indices." | 1.40 | Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride-induced hypertensive rats. ( Akindahunsi, AA; Akinmoladun, AC; Crown, OO; Olaleye, MT, 2014) |
| "Nifedipine is an L-type voltage-dependent calcium channel blocker." | 1.40 | Effect of nifedipine on hippocampal neuron number in penicillin-induced epileptic rats. ( Akdogan, I; Kaya, E; Yilmaz, I; Yonguc, GN, 2014) |
| "Nifedipine is a widely used anti-anginal and anti-hypertensive agent." | 1.40 | Nifedipine-induced histological changes in the parotid glands of hypertensive rats. ( Daskala, I; Kotsiou, A; Seferos, N; Tesseromatis, C; Tsamouri, M, 2014) |
| " On the other hand, under the condition of Ang II-induced hypertension, administration of a hypotensive dosage of cilnidipine showed no effect on the plasma aldosterone levels, whereas a hypotensive dosage of nifedipine significantly increased the plasma aldosterone levels." | 1.38 | L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. ( Aritomi, S; Konda, T; Yoshimura, M, 2012) |
| "Nilvadipine was administered from P7 to P28." | 1.37 | AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency. ( Allocca, M; Auricchio, A; Di Vicino, U; Iodice, C; Manfredi, A, 2011) |
| "Nifedipine alone was not sufficient to promote gingival enlargement or periodontal destruction in the absence of the ligature." | 1.36 | Effect of nifedipine on gingival enlargement and periodontal breakdown in ligature-induced periodontitis in rats. ( Fernandes, MI; Gaio, EJ; Oppermann, RV; Rados, PV; Rösing, CK; Susin, C, 2010) |
| "The ability of CCBs to produce catalepsy in mice was also evaluated in the study." | 1.36 | Anti-psychotic and sedative effect of calcium channel blockers in mice. ( Bakre, TO; Onwuchekwa, C; Umukoro, S, 2010) |
| "Nimodipine was further studied using a higher and escalating doses of morphine (20-30 mg/kg twice daily for 14 days)." | 1.35 | Nimodipine is more effective than nifedipine in attenuating morphine tolerance on chronic co-administration in the rat tail-flick test. ( Gupta, A; Mishra, P; Ray, SB; Verma, D; Wadhwa, S, 2008) |
| "Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group." | 1.35 | Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. ( Arsenault, M; Beaudoin, J; Champetier, S; Couet, J; Lachance, D; Plante, E; Roussel, E, 2009) |
| " In both age groups, chronic nifedipine administration reduced neurogenic contractions of isolated superior mesenteric artery, but did not significantly affect the dose-response curve to exogenous noradrenaline in 8-week-old rats." | 1.35 | Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. ( Török, J; Zemančíková, A, 2009) |
| "Nifedipine treatment decreased serum insulin level to one fifth of that in KK-A(y) mice without nifedipine." | 1.35 | Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2008) |
| "Treatment with nifedipine resulted in a significant inhibition of the progression of AAA such as aneurismal dilation at 14 and 28 days compared to the control (week 2: control, 2." | 1.35 | Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. ( Izawa, K; Kunugiza, Y; Morishita, R; Ogihara, T; Osako, MK; Tomita, N; Yamasaki, K, 2008) |
| "The treatment with nifedipine prevented the reduction of sexual behavior and the increase of plasma PRL, but did not alter the reduction of plasma testosterone and FSH and spermatogenesis of 2K/1C rats." | 1.34 | Effects of renovascular hypertension on reproductive function in male rats. ( Breigeiron, MK; Lucion, AB; Sanvitto, GL, 2007) |
| "Edema was assessed plethysmometrically by evaluating paw volume changes." | 1.34 | Adrenalectomy potentiates the anti-inflammatory activity of a calcium channel blocker. ( Banerjee, A; Nivsarkar, M; Vaghasiya, R, 2007) |
| "Cerebral aneurysm rupture and subarachnoid hemorrhage (SAH) inflict disability and death on thousands of individuals each year." | 1.33 | Emergence of a R-type Ca2+ channel (CaV 2.3) contributes to cerebral artery constriction after subarachnoid hemorrhage. ( Honda, A; Ishiguro, M; Russell, SR; Tranmer, BI; Wellman, GC; Wellman, TL, 2005) |
| "Treatment with nifedipine (10, 20 mg/kg) significantly improved the renal dysfunction, tissue and urine total nitric oxide levels, and renal oxidative stress and prevented the alterations in renal morphology." | 1.33 | Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine. ( Chander, V; Chopra, K, 2005) |
| "Septic shock has a high mortality rate due to the hypotension and circulatory disorder that occurs during its pathogenesis." | 1.33 | Effects of verapamil and nifedipine on different parameters in lipopolysaccharide-induced septic shock. ( Erol, K; Kilic, FS; Sirmagul, B; Tunc, O; Yildirim, E, 2006) |
| "The development of Alzheimer's disease (AD) is generally thought to correlate with cerebral accumulation of Abeta." | 1.32 | Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. ( Crawford, F; Crescentini, R; Humphrey, J; Mullan, M; Paris, D; Patel, N; Quadros, A, 2004) |
| "When isosorbide dinitrate (ISDN, 1 mM) was applied during isometric measurement, 18." | 1.31 | The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil. ( Hirai, M; Iino, S; Kondo, T; Takeshita, K; Tanaka, T, 2002) |
| "Single ECT had no significant effect on thermal hyperalgesia or mechanical allodynia." | 1.30 | The effect of electroconvulsive treatment on thermal hyperalgesia and mechanical allodynia in a rat model of peripheral neuropathy. ( Inoue, T; Shibata, M; Shimizu, T; Wakisaka, S; Yoshiya, I, 1998) |
| "Nifedipine treatment for 5 days significantly reduced the blood pressure in cadmium-hypertensive and normotensive rats." | 1.30 | The effects of short-term nifedipine treatment on responsiveness of aortic rings of cadmium-hypertensive rats. ( Oğütman, C; Ozdem, SS, 1999) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 1.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| "Nifedipine treatment significantly prevented STZ-induced increase in cholesterol and triglyceride levels." | 1.29 | Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. ( Bangaru, RA; Gandhi, TP; Goyal, RK; Satia, MC; Shah, TS, 1995) |
| "Hypertension is commonly associated with an endothelial dysfunction that may contribute to the rise in blood pressure." | 1.29 | Impairement of endothelium-dependent relaxation in chronic two-kidney, one clip hypertensive rats. ( Choi, KC; Kang, YJ; Kim, WJ; Lee, J; Park, JW; Woo, YJ; Yoo, KJ; Yoo, KS, 1994) |
| "The nifedipine-treated rats (experimental group) were fed a caries-inducing diet containing nifedipine either with or without infection, while the nifedipine-untreated rats (control group) were fed the same diet, similarly with or without the infection." | 1.29 | Nifedipine-induced gingival overgrowth in the presence or absence of gingival inflammation in rats. ( Ishida, H; Kato, K; Loyola-Rodriguez, JP; Morisaki, I; Nagata, T, 1993) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 1.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| "Acute inflammation was associated with enlarged colonic perimeter." | 1.29 | Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. ( Guarner, F; Malagelada, JR; Mourelle, M; Salas, A; Vilaseca, J, 1996) |
| " The rats were observed for toxic signs and survival over a period of 15 days." | 1.29 | Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats. ( Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1996) |
| "The seizures were predominantly clonic jerks accompanied by large spikes and slow waves lasting for 30-60s." | 1.29 | Effect of antiepileptic drugs and calcium channel blocker on hyperthermic seizures in rats: animal model for hot water epilepsy. ( Satishchandra, P; Shankar, SK; Ullal, GR, 1996) |
| "Pretreatment with nifedipine (3 x 10(-8) M) prevented the rise in LVEDP induced by pacing tachycardia." | 1.28 | Effects of nifedipine on diastolic abnormalities in low-flow and pacing-induced ischemia in isolated rat hearts. ( Iizuka, M; Ikenouchi, H; Momomura, S; Serizawa, T; Sugimoto, T, 1991) |
| "Hypertension was developed in 5-week-old male rats fed a low calcium diet, which evokes hypocalcemia and nutritional hyperparathyroidism, for 2 weeks." | 1.28 | Elevation of blood pressure in young rats fed a low calcium diet. Effects of nifedipine and captopril. ( Arai, M; Matsumoto, S; Nagatsu, T; Shamoto, T; Togari, A, 1989) |
| "Nitrendipine proved to be a potent hypotensive agent in sham shock cats when infused over a 4 h period (156 +/- 9 to 90 +/- 5 mm Hg) (P less than 0." | 1.27 | Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock. ( Hock, CE; Lefer, AM; Su, JY, 1984) |
| "Verapamil was more active than nifedipine in both models." | 1.27 | Evaluation of cardiac anoxia and ischemia models in the rat using calcium antagonists. ( Jacobs, LW; Rosenberger, LB; Stanton, HC, 1984) |
| " At a dosage of 20 mg/kg/day, drug therapy in each case significantly prolonged the functional ability of the dystrophic chickens as quantitated regularly by a standardized test for righting ability." | 1.27 | In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy. ( Heffner, RR; Hudecki, MS; Pollina, CM, 1984) |
| "When the mural thrombus was removed from 14 grafts, a median 73% of the platelets were located in the interface between thrombus and graft." | 1.27 | Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. ( Chesebro, JH; Dewanjee, MK; Fuster, V; Kaye, MP; Pumphrey, CW; Vlietstra, RE, 1983) |
| "In the absence of coronary stenosis, intracoronary infusion of ergonovine (0." | 1.27 | Myocardial ischaemia produced by ergonovine-induced vasoconstriction during preexisting coronary stenosis: experimental conditions for the geometric theory. ( Fukuzaki, H; Kawashima, S; Okada, T; Sakamoto, S; Yokoyama, M, 1985) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 1.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| " Dosage of all drugs was adjusted to reduce mean aortic pressure by no more than 5 mmHg." | 1.26 | Improved performance of ischemic canine myocardium in response to nifedipine and diltiazem. ( Henry, PD; Pérez, JE; Sobel, BE, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (17.05) | 18.7374 |
| 1990's | 45 (20.74) | 18.2507 |
| 2000's | 64 (29.49) | 29.6817 |
| 2010's | 61 (28.11) | 24.3611 |
| 2020's | 10 (4.61) | 2.80 |
| Authors | Studies |
|---|---|
| Urbahns, K | 1 |
| Horváth, E | 1 |
| Stasch, JP | 1 |
| Mauler, F | 1 |
| Beebe, X | 1 |
| Darczak, D | 1 |
| Henry, RF | 1 |
| Vortherms, T | 1 |
| Janis, R | 1 |
| Namovic, M | 1 |
| Donnelly-Roberts, D | 1 |
| Kage, KL | 1 |
| Surowy, C | 1 |
| Milicic, I | 1 |
| Niforatos, W | 1 |
| Swensen, A | 1 |
| Marsh, KC | 2 |
| Wetter, JM | 1 |
| Franklin, P | 1 |
| Baker, S | 1 |
| Zhong, C | 1 |
| Simler, G | 1 |
| Gomez, E | 1 |
| Boyce-Rustay, JM | 1 |
| Zhu, CZ | 1 |
| Stewart, AO | 1 |
| Jarvis, MF | 1 |
| Scott, VE | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Huang, K | 3 |
| Wu, Y | 3 |
| Zhang, Y | 4 |
| Youn, JY | 3 |
| Cai, H | 3 |
| Tejero, R | 1 |
| Alsakkal, M | 1 |
| Hennlein, L | 1 |
| Lopez-Cabello, AM | 1 |
| Jablonka, S | 1 |
| Tabares, L | 1 |
| Lee, Y | 1 |
| Lee, JE | 1 |
| Lee, AR | 1 |
| Choi, EY | 1 |
| Choi, IS | 1 |
| Kim, SJ | 1 |
| Li, H | 1 |
| Zhang, LK | 1 |
| Li, SF | 1 |
| Zhang, SF | 1 |
| Wan, WW | 1 |
| Zhang, YL | 1 |
| Xin, QL | 1 |
| Dai, K | 1 |
| Hu, YY | 1 |
| Wang, ZB | 1 |
| Zhu, XT | 1 |
| Fang, YJ | 1 |
| Cui, N | 1 |
| Zhang, PH | 1 |
| Yuan, C | 1 |
| Lu, QB | 1 |
| Bai, JY | 1 |
| Deng, F | 1 |
| Xiao, GF | 1 |
| Liu, W | 2 |
| Peng, K | 1 |
| Ryu, B | 1 |
| Choi, SW | 1 |
| Lee, SG | 1 |
| Jeong, YH | 1 |
| Kim, U | 1 |
| Kim, J | 1 |
| Jung, CR | 1 |
| Chung, HM | 1 |
| Park, JH | 1 |
| Kim, CY | 1 |
| Lin, YC | 1 |
| Wang, JC | 1 |
| Wu, MS | 1 |
| Lin, YF | 1 |
| Chen, CR | 1 |
| Chen, CY | 1 |
| Chen, KC | 1 |
| Peng, CC | 1 |
| Sardesai, M | 1 |
| Shende, P | 1 |
| Aali, E | 1 |
| Ghaznavi, H | 1 |
| Soltanpour, MS | 1 |
| Mahmoudian, M | 1 |
| Shafiei, M | 1 |
| Uchendu, IK | 1 |
| Agu, CE | 1 |
| Nnedu, EB | 1 |
| Chukwu, IJ | 1 |
| El-Feky, YA | 1 |
| Fares, AR | 1 |
| Zayed, G | 1 |
| El-Telbany, RFA | 1 |
| Ahmed, KA | 1 |
| El-Telbany, DFA | 1 |
| Stojanović, M | 1 |
| Prostran, M | 1 |
| Janković, R | 1 |
| Radenković, M | 1 |
| Mante, PK | 1 |
| Adongo, DW | 1 |
| Woode, E | 1 |
| Zhou, Q | 1 |
| Dong, J | 1 |
| Xu, T | 1 |
| Cai, X | 1 |
| Normann, C | 1 |
| Frase, S | 1 |
| Haug, V | 1 |
| von Wolff, G | 1 |
| Clark, K | 1 |
| Münzer, P | 1 |
| Dorner, A | 1 |
| Scholliers, J | 1 |
| Horn, M | 1 |
| Vo Van, T | 1 |
| Seifert, G | 1 |
| Serchov, T | 1 |
| Biber, K | 1 |
| Nissen, C | 1 |
| Klugbauer, N | 1 |
| Bischofberger, J | 1 |
| Yue, ZW | 1 |
| Wang, YL | 1 |
| Xiao, B | 1 |
| Feng, L | 1 |
| Sagawa, H | 1 |
| Hoshino, S | 1 |
| Yoshioka, K | 1 |
| Ding, WG | 1 |
| Omatsu-Kanbe, M | 1 |
| Nakagawa, M | 1 |
| Maruo, Y | 1 |
| Matsuura, H | 1 |
| Eraslan, E | 1 |
| Tanyeli, A | 1 |
| Polat, E | 2 |
| Imanishi, M | 1 |
| Izawa-Ishizawa, Y | 2 |
| Sakurada, T | 1 |
| Kohara, Y | 1 |
| Horinouchi, Y | 2 |
| Sairyo, E | 2 |
| Zamami, Y | 1 |
| Takechi, K | 1 |
| Chuma, M | 1 |
| Fukushima, K | 1 |
| Ikeda, Y | 3 |
| Fujino, H | 1 |
| Yoshizumi, M | 1 |
| Tsuchiya, K | 2 |
| Tamaki, T | 2 |
| Ishizawa, K | 2 |
| Ikenaka, K | 1 |
| Tsukada, Y | 1 |
| Giles, AC | 1 |
| Arai, T | 1 |
| Nakadera, Y | 1 |
| Nakano, S | 1 |
| Kawai, K | 1 |
| Mochizuki, H | 1 |
| Katsuno, M | 1 |
| Sobue, G | 1 |
| Mori, I | 1 |
| Jiang, X | 1 |
| Luttrell, I | 1 |
| Chitaley, K | 1 |
| Yang, CC | 1 |
| Shimizu, S | 1 |
| Saito, M | 1 |
| Oiwa, H | 1 |
| Ohmasa, F | 1 |
| Tsounapi, P | 1 |
| Oikawa, R | 1 |
| Dimitriadis, F | 1 |
| Martin, DT | 1 |
| Satoh, I | 1 |
| Kinoshita, Y | 1 |
| Tomita, S | 1 |
| Olaleye, MT | 1 |
| Crown, OO | 1 |
| Akinmoladun, AC | 1 |
| Akindahunsi, AA | 1 |
| Akindele, AJ | 1 |
| Adeneye, AA | 1 |
| Olatoye, F | 1 |
| Benebo, AS | 1 |
| Shi, X | 1 |
| Fu, Y | 1 |
| Liao, D | 1 |
| Chen, Y | 1 |
| Liu, J | 1 |
| Zicha, J | 2 |
| Dobešová, Z | 2 |
| Behuliak, M | 1 |
| Pintérová, M | 1 |
| Kuneš, J | 2 |
| Vaněčková, I | 1 |
| Yilmaz, I | 1 |
| Akdogan, I | 1 |
| Kaya, E | 1 |
| Yonguc, GN | 1 |
| Seferos, N | 1 |
| Daskala, I | 1 |
| Kotsiou, A | 1 |
| Tsamouri, M | 1 |
| Tesseromatis, C | 1 |
| Xia, Y | 1 |
| Liu, R | 1 |
| Chen, R | 1 |
| Tian, Q | 1 |
| Zeng, K | 1 |
| Hu, J | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Wang, XC | 1 |
| Wang, JZ | 1 |
| Li, WL | 1 |
| Wu, CH | 1 |
| Yang, J | 1 |
| Tang, M | 1 |
| Chen, LJ | 1 |
| Zhao, SL | 1 |
| Wang, RX | 1 |
| He, RL | 1 |
| Jiao, HX | 1 |
| Dai, M | 1 |
| Mu, YP | 1 |
| Hu, Y | 2 |
| Wu, ZJ | 1 |
| Sham, JS | 1 |
| Lin, MJ | 1 |
| Kojima, A | 1 |
| Matsumoto, A | 1 |
| Nishida, H | 1 |
| Reien, Y | 1 |
| Iwata, K | 1 |
| Shirayama, T | 1 |
| Yabe-Nishimura, C | 1 |
| Nakaya, H | 1 |
| Alp Yildirim, FI | 1 |
| Eker Kizilay, D | 1 |
| Ergin, B | 1 |
| Balci Ekmekçi, Ö | 1 |
| Topal, G | 1 |
| Kucur, M | 1 |
| Demirci Tansel, C | 1 |
| Uydeş Doğan, BS | 1 |
| He, D | 1 |
| Lu, Y | 1 |
| Hu, H | 1 |
| Zhang, J | 2 |
| Qin, B | 1 |
| Wang, Y | 1 |
| Xing, S | 1 |
| Xi, Q | 1 |
| Wang, S | 1 |
| Jain, S | 1 |
| Sharma, BM | 1 |
| Sharma, B | 1 |
| Kiriyama, A | 1 |
| Honbo, A | 1 |
| Nishimura, A | 1 |
| Shibata, N | 1 |
| Iga, K | 1 |
| Lovell, MA | 1 |
| Lynn, BC | 1 |
| Fister, S | 1 |
| Bradley-Whitman, M | 1 |
| Murphy, MP | 1 |
| Beckett, TL | 1 |
| Norris, CM | 1 |
| Cao, X | 1 |
| Nakamura, Y | 1 |
| Wada, T | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Zhu, B | 1 |
| Xu, B | 1 |
| Takahara, A | 1 |
| Saitoh, M | 1 |
| Sugiyama, A | 1 |
| Sbaraglini, ML | 1 |
| Bellera, CL | 1 |
| Fraccaroli, L | 1 |
| Larocca, L | 1 |
| Carrillo, C | 1 |
| Talevi, A | 1 |
| Alba Soto, CD | 1 |
| Murphy, CM | 1 |
| Williams, C | 1 |
| Quinn, ME | 1 |
| Nicholson, B | 1 |
| Shoe, T | 1 |
| Beuhler, MC | 1 |
| Kerns, WP | 1 |
| Fukunaga, Y | 1 |
| Abe, Y | 1 |
| Hashimoto, I | 1 |
| Ray, SB | 1 |
| Mishra, P | 1 |
| Verma, D | 1 |
| Gupta, A | 1 |
| Wadhwa, S | 1 |
| Kanai, A | 1 |
| Ghais, NS | 1 |
| Grace, AA | 1 |
| Huang, CL | 1 |
| Cui, B | 1 |
| Cheng, YS | 1 |
| Dai, DZ | 1 |
| Li, N | 1 |
| Zhang, TT | 1 |
| Dai, Y | 1 |
| Ishiguro, K | 1 |
| Hayashi, K | 1 |
| Sasamura, H | 1 |
| Sakamaki, Y | 1 |
| Itoh, H | 1 |
| Yamada, T | 1 |
| Nagata, K | 1 |
| Cheng, XW | 1 |
| Obata, K | 1 |
| Saka, M | 1 |
| Miyachi, M | 1 |
| Naruse, K | 2 |
| Nishizawa, T | 1 |
| Noda, A | 1 |
| Izawa, H | 1 |
| Kuzuya, M | 1 |
| Okumura, K | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Shimada, M | 1 |
| Xiao, J | 1 |
| Hu, D | 1 |
| Matsumori, A | 2 |
| Plante, E | 1 |
| Lachance, D | 1 |
| Beaudoin, J | 1 |
| Champetier, S | 1 |
| Roussel, E | 1 |
| Arsenault, M | 1 |
| Couet, J | 1 |
| Pambo-Pambo, A | 1 |
| Durand, J | 1 |
| Gueritaud, JP | 1 |
| Smeda, JS | 3 |
| McGuire, JJ | 1 |
| Daneshtalab, N | 1 |
| Zemančíková, A | 1 |
| Török, J | 1 |
| Zhang, M | 1 |
| Leung, FP | 1 |
| Huang, Y | 1 |
| Bian, ZX | 1 |
| Shibasaki, M | 1 |
| Kurokawa, K | 1 |
| Ohkuma, S | 2 |
| Luo, Q | 1 |
| Xuan, WL | 1 |
| Xi, F | 1 |
| Liao, YL | 1 |
| Kitakaze, M | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 2 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Fernandes, MI | 1 |
| Gaio, EJ | 1 |
| Susin, C | 1 |
| Rösing, CK | 1 |
| Oppermann, RV | 1 |
| Rados, PV | 1 |
| Ago, T | 1 |
| Yang, Y | 1 |
| Zhai, P | 1 |
| Sadoshima, J | 1 |
| Iwai, M | 2 |
| Kanno, H | 1 |
| Inaba, S | 1 |
| Senba, I | 1 |
| Sone, H | 1 |
| Nakaoka, H | 1 |
| Horiuchi, M | 2 |
| Xu, J | 1 |
| Liu, ZA | 1 |
| Pei, DS | 1 |
| Xu, TJ | 1 |
| Syyong, HT | 1 |
| Chung, AW | 1 |
| van Breemen, C | 1 |
| Yamamoto, E | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Ishida, S | 1 |
| Koto, T | 1 |
| Nagai, N | 1 |
| Oike, Y | 2 |
| Sakamoto, K | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Ishii, K | 2 |
| Allocca, M | 1 |
| Manfredi, A | 1 |
| Iodice, C | 1 |
| Di Vicino, U | 1 |
| Auricchio, A | 1 |
| Vriens, J | 1 |
| Owsianik, G | 1 |
| Hofmann, T | 1 |
| Philipp, SE | 1 |
| Stab, J | 1 |
| Chen, X | 1 |
| Benoit, M | 1 |
| Xue, F | 1 |
| Janssens, A | 1 |
| Kerselaers, S | 1 |
| Oberwinkler, J | 1 |
| Vennekens, R | 1 |
| Gudermann, T | 1 |
| Nilius, B | 1 |
| Voets, T | 1 |
| Tian, Z | 1 |
| Miyata, K | 1 |
| Tabata, M | 1 |
| Yano, M | 1 |
| Tazume, H | 1 |
| Aoi, J | 1 |
| Takahashi, O | 1 |
| Araki, K | 1 |
| Kawasuji, M | 1 |
| Nakagami, H | 1 |
| Shimamura, M | 1 |
| Miyake, T | 1 |
| Shimosato, T | 1 |
| Minobe, N | 1 |
| Moritani, T | 1 |
| Kiomy Osako, M | 1 |
| Nakagami, F | 1 |
| Koriyama, H | 1 |
| Kyutoku, M | 1 |
| Shimizu, H | 1 |
| Katsuya, T | 1 |
| Morishita, R | 2 |
| Aritomi, S | 1 |
| Konda, T | 1 |
| Yoshimura, M | 1 |
| Bussek, A | 1 |
| Schmidt, M | 1 |
| Bauriedl, J | 1 |
| Ravens, U | 1 |
| Wettwer, E | 1 |
| Lohmann, H | 1 |
| Rinker, B | 1 |
| Fink, BF | 1 |
| Stoker, AR | 1 |
| Milan, ME | 1 |
| Nelson, PT | 1 |
| Kumfu, S | 1 |
| Chattipakorn, S | 1 |
| Chinda, K | 1 |
| Fucharoen, S | 1 |
| Chattipakorn, N | 1 |
| Umukoro, S | 1 |
| Bakre, TO | 1 |
| Onwuchekwa, C | 1 |
| S K S, S | 1 |
| P, H | 1 |
| Mathew, T | 1 |
| S, S | 1 |
| M, C | 1 |
| Yang, CH | 1 |
| Huang, CC | 1 |
| Hsu, KS | 1 |
| Mayama, C | 1 |
| Ota, T | 1 |
| Tomidokoro, A | 1 |
| Araie, M | 1 |
| Damasceno, DD | 1 |
| Ferreira, AJ | 1 |
| Doretto, MC | 1 |
| Almeida, AP | 1 |
| Balkanci, ZD | 1 |
| Pehlivanoğlu, B | 1 |
| Bayrak, S | 1 |
| Karabulut, I | 1 |
| Karaismailoğlu, S | 1 |
| Erdem, A | 1 |
| Dudley, JA | 1 |
| Weir, RK | 1 |
| Yan, TC | 1 |
| Grabowska, EM | 1 |
| Grimmé, AJ | 1 |
| Amini, S | 1 |
| Stephens, DN | 1 |
| Hunt, SP | 1 |
| Stanford, SC | 1 |
| Payne, GW | 1 |
| El-Abhar, HS | 1 |
| Shaalan, M | 1 |
| Barakat, M | 1 |
| El-Denshary, ES | 1 |
| Choi, BR | 1 |
| Nho, W | 1 |
| Liu, T | 1 |
| Salama, G | 1 |
| Shimizu, Y | 1 |
| Kataoka, M | 1 |
| Seto, H | 1 |
| Kido, J | 1 |
| Nagata, T | 3 |
| Tanaka, T | 1 |
| Iino, S | 1 |
| Takeshita, K | 1 |
| Kondo, T | 1 |
| Hirai, M | 1 |
| Chan, P | 1 |
| Wong, KL | 1 |
| Liu, IM | 1 |
| Tzeng, TF | 1 |
| Yang, TL | 1 |
| Cheng, JT | 1 |
| Altura, BM | 1 |
| Kostellow, AB | 1 |
| Zhang, A | 1 |
| Morrill, GA | 1 |
| Gupta, RK | 1 |
| Altura, BT | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Ito, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| Takano, Y | 2 |
| Ohguro, H | 3 |
| Ohguro, I | 1 |
| Yamazaki, H | 2 |
| Mamiya, K | 1 |
| Ishikawa, F | 1 |
| Nakazawa, M | 3 |
| Liashenko, VP | 2 |
| Lukashov, SM | 2 |
| Paris, D | 1 |
| Quadros, A | 1 |
| Humphrey, J | 1 |
| Patel, N | 1 |
| Crescentini, R | 1 |
| Crawford, F | 1 |
| Mullan, M | 1 |
| Feng, QZ | 1 |
| Li, TD | 1 |
| Wang, ZX | 1 |
| Yi, J | 1 |
| Wang, L | 1 |
| Yang, TS | 1 |
| Russo, E | 1 |
| Constanti, A | 1 |
| Ferreri, G | 1 |
| Citraro, R | 1 |
| De Sarro, G | 1 |
| Fryer, RM | 1 |
| Preusser, LC | 1 |
| Calzadilla, SV | 1 |
| Xu, H | 1 |
| Cox, BF | 1 |
| Lin, CT | 1 |
| Gopalakrishnan, M | 1 |
| Reinhart, GA | 1 |
| Spalloni, A | 1 |
| Pascucci, T | 1 |
| Albo, F | 1 |
| Ferrari, F | 1 |
| Puglisi-Allegra, S | 1 |
| Zona, C | 1 |
| Bernardi, G | 1 |
| Longone, P | 1 |
| Ishiguro, M | 1 |
| Wellman, TL | 1 |
| Honda, A | 1 |
| Russell, SR | 1 |
| Tranmer, BI | 1 |
| Wellman, GC | 1 |
| Miroshnichenko, AO | 1 |
| Forrest, A | 1 |
| Molleman, A | 1 |
| Parsons, M | 1 |
| Abdelmalik, PA | 1 |
| Burnham, WM | 1 |
| Carlen, PL | 1 |
| Katsura, M | 1 |
| Torigoe, F | 1 |
| Hayashida, S | 1 |
| Honda, T | 1 |
| Tsujimura, A | 1 |
| Di Filippo, C | 1 |
| Lampa, E | 1 |
| Forgione, A | 1 |
| Capuano, A | 1 |
| Rossi, F | 1 |
| D'Amico, M | 1 |
| Chander, V | 1 |
| Chopra, K | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 2 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Sathasivam, S | 1 |
| Grierson, AJ | 1 |
| Shaw, PJ | 1 |
| Okuda, N | 1 |
| Hayashi, T | 1 |
| Mori, T | 2 |
| Inamoto, S | 1 |
| Okabe, M | 1 |
| Mieno, S | 1 |
| Horimoto, H | 1 |
| Kitaura, Y | 1 |
| Hinton, M | 1 |
| Mellow, L | 1 |
| Halayko, AJ | 1 |
| Gutsol, A | 1 |
| Dakshinamurti, S | 1 |
| Radin, MJ | 1 |
| Chu, YY | 1 |
| Hoepf, TM | 1 |
| McCune, SA | 1 |
| Shih, HC | 1 |
| Lee, TH | 1 |
| Chen, SC | 1 |
| Li, CY | 1 |
| Shibuya, T | 1 |
| Sirmagul, B | 1 |
| Kilic, FS | 1 |
| Tunc, O | 1 |
| Yildirim, E | 1 |
| Erol, K | 1 |
| Bagate, K | 1 |
| Meiring, JJ | 1 |
| Gerlofs-Nijland, ME | 1 |
| Cassee, FR | 1 |
| Wiegand, H | 1 |
| Osornio-Vargas, A | 1 |
| Borm, PJ | 1 |
| Blake, BL | 1 |
| Muehlmann, AM | 1 |
| Egami, K | 1 |
| Breese, GR | 1 |
| Devine, DP | 1 |
| Jinnah, HA | 1 |
| Ikeda, J | 1 |
| Matsubara, M | 1 |
| Yao, K | 1 |
| Breigeiron, MK | 1 |
| Lucion, AB | 1 |
| Sanvitto, GL | 1 |
| Takeuchi, K | 1 |
| Mizukoshi, S | 1 |
| Gould, S | 1 |
| Westwood, FR | 1 |
| Curwen, JO | 1 |
| Ashton, SE | 1 |
| Roberts, DW | 1 |
| Lovick, SC | 1 |
| Ryan, AJ | 1 |
| Tsukuda, K | 1 |
| Mogi, M | 1 |
| Li, JM | 1 |
| Iwanami, J | 1 |
| Min, LJ | 1 |
| Sakata, A | 1 |
| Fujita, T | 1 |
| Tomita, N | 1 |
| Yamasaki, K | 1 |
| Izawa, K | 1 |
| Kunugiza, Y | 1 |
| Osako, MK | 1 |
| Ogihara, T | 1 |
| Toronyi, E | 1 |
| Aoki, T | 1 |
| Kataoka, H | 1 |
| Ishibashi, R | 1 |
| Nozaki, K | 1 |
| Hashimoto, N | 1 |
| Banerjee, A | 1 |
| Vaghasiya, R | 1 |
| Nivsarkar, M | 1 |
| Sabino, B | 1 |
| Lessa, MA | 1 |
| Nascimento, AR | 1 |
| Rodrigues, CA | 1 |
| Henriques, Md | 1 |
| Garzoni, LR | 1 |
| Levy, BI | 1 |
| Tibiriçá, E | 1 |
| Robinson, LA | 1 |
| Braimbridge, MV | 2 |
| Hearse, DJ | 3 |
| Lamping, KA | 1 |
| Warltier, DC | 1 |
| Hardman, HF | 1 |
| Gross, GJ | 1 |
| Weir, B | 1 |
| Burke, TJ | 1 |
| Arnold, PE | 1 |
| Gordon, JA | 1 |
| Bulger, RE | 1 |
| Dobyan, DC | 1 |
| Schrier, RW | 1 |
| Parratt, JR | 1 |
| Coker, SJ | 1 |
| Hock, CE | 1 |
| Su, JY | 1 |
| Lefer, AM | 1 |
| Rosenberger, LB | 1 |
| Jacobs, LW | 1 |
| Stanton, HC | 1 |
| Hudecki, MS | 1 |
| Pollina, CM | 1 |
| Heffner, RR | 1 |
| Pumphrey, CW | 1 |
| Fuster, V | 1 |
| Dewanjee, MK | 1 |
| Chesebro, JH | 1 |
| Vlietstra, RE | 1 |
| Kaye, MP | 1 |
| Geary, GG | 1 |
| Smith, GT | 1 |
| Suehiro, GT | 1 |
| McNamara, JJ | 1 |
| Mulvany, MJ | 1 |
| Korsgaard, N | 1 |
| Nyborg, N | 1 |
| Pérez, JE | 1 |
| Sobel, BE | 1 |
| Henry, PD | 1 |
| Dohi, Y | 1 |
| Criscione, L | 1 |
| Pfeiffer, K | 1 |
| Lüscher, TF | 1 |
| Shah, TS | 1 |
| Satia, MC | 1 |
| Gandhi, TP | 1 |
| Bangaru, RA | 1 |
| Goyal, RK | 1 |
| Jiang, GC | 1 |
| Iwanov, V | 1 |
| Moulds, RF | 1 |
| Choi, KC | 1 |
| Woo, YJ | 1 |
| Park, JW | 1 |
| Lee, J | 1 |
| Kim, WJ | 1 |
| Yoo, KJ | 1 |
| Yoo, KS | 1 |
| Kang, YJ | 1 |
| Fleckenstein-Grün, G | 1 |
| Thimm, F | 1 |
| Czirfuzs, A | 1 |
| Matyas, S | 1 |
| Frey, M | 1 |
| Hattingh, P | 1 |
| Coetzee, A | 1 |
| Harper, I | 1 |
| Genade, S | 1 |
| Lochner, A | 1 |
| Morisaki, I | 2 |
| Kato, K | 1 |
| Loyola-Rodriguez, JP | 1 |
| Ishida, H | 2 |
| Harada, K | 1 |
| Fukata, Y | 1 |
| Miwa, A | 1 |
| Kaneta, S | 1 |
| Fukushima, H | 1 |
| Ogawa, N | 1 |
| Norman, PE | 1 |
| House, AK | 1 |
| Takahashi, T | 1 |
| Fukai, T | 1 |
| Hata, H | 1 |
| Kasuya, H | 1 |
| Kuga, T | 1 |
| Egashira, K | 1 |
| Takeshita, A | 1 |
| Kishimoto, T | 1 |
| Okamiya, Y | 1 |
| Aoki, K | 1 |
| Ota, M | 1 |
| Hoshina, K | 1 |
| Takeshita, T | 1 |
| Inoue, M | 1 |
| Harada, Y | 1 |
| Watanabe, K | 1 |
| Mori, C | 1 |
| Tanaka, O | 1 |
| Motomura, S | 1 |
| Ishigai, Y | 1 |
| Fukuzawa, A | 1 |
| Chiba, K | 1 |
| Shibano, T | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Mourelle, M | 1 |
| Vilaseca, J | 1 |
| Guarner, F | 1 |
| Salas, A | 1 |
| Malagelada, JR | 1 |
| Whitehurst, VE | 1 |
| Joseph, X | 1 |
| Vick, JA | 1 |
| Alleva, FR | 1 |
| Balazs, T | 1 |
| Hultgren, HN | 1 |
| Nishikawa, S | 1 |
| Oka, T | 1 |
| Patole, SK | 1 |
| Finer, NN | 1 |
| al-Dohayan, AD | 1 |
| al-Tuwaijri, AS | 1 |
| Homsi, E | 1 |
| Oliveira Dias, EP | 1 |
| Garcia, WE | 1 |
| Gontijo, JA | 1 |
| Figueiredo, JF | 1 |
| Ullal, GR | 1 |
| Satishchandra, P | 1 |
| Shankar, SK | 1 |
| Simko, V | 1 |
| Joseph, D | 1 |
| Michael, S | 1 |
| Moran, A | 1 |
| Martín, E | 1 |
| Velasco, C | 1 |
| Martín, ML | 1 |
| San Roman, L | 1 |
| Caballero, E | 1 |
| Puebla, P | 1 |
| Medarde, M | 1 |
| San Feliciano, A | 1 |
| Vincent, M | 1 |
| Samani, NJ | 1 |
| Gauguier, D | 1 |
| Thompson, JR | 1 |
| Lathrop, GM | 1 |
| Sassard, J | 1 |
| Hardy, KJ | 1 |
| Tancheroen, S | 1 |
| Shulkes, A | 1 |
| Bouskela, E | 1 |
| Cyrino, FZ | 1 |
| Conde, CM | 1 |
| Garcia, AA | 1 |
| Shibata, M | 1 |
| Wakisaka, S | 1 |
| Inoue, T | 1 |
| Shimizu, T | 1 |
| Yoshiya, I | 1 |
| Fu, E | 2 |
| Nieh, S | 1 |
| Hsiao, CT | 1 |
| Hsieh, YD | 1 |
| Wikesjö, UM | 1 |
| Shen, EC | 1 |
| Hermann, M | 1 |
| Schulz, E | 1 |
| Ruschitzka, F | 1 |
| Müller, GA | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Adachi, C | 1 |
| Yoshimoto, T | 1 |
| Mishina, N | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Demura, H | 1 |
| Ozdem, SS | 1 |
| Oğütman, C | 1 |
| Dimo, T | 1 |
| Rakotonirina, A | 1 |
| Tan, PV | 1 |
| Dongo, E | 1 |
| Dongmo, AB | 1 |
| Kamtchouing, P | 1 |
| Azay, J | 1 |
| Abegaz, BM | 1 |
| Cros, G | 1 |
| Ngadjui, TB | 1 |
| Tamura, M | 1 |
| Kurumatani, H | 1 |
| Matsushita, T | 1 |
| Chiu, HC | 1 |
| Chiang, CY | 1 |
| Liu, D | 1 |
| McElmurray, JH | 1 |
| Mukherjee, R | 1 |
| Patterson, TM | 1 |
| Goldberg, A | 1 |
| King, MK | 1 |
| Hendrick, JW | 1 |
| Gay, DM | 1 |
| Clair, MJ | 1 |
| Jolly, JR | 1 |
| Spinale, FG | 1 |
| Amano, H | 1 |
| Amano, T | 1 |
| Matsubayashi, H | 1 |
| Ishihara, K | 1 |
| Serikawa, T | 1 |
| Sasa, M | 1 |
| Cui, S | 1 |
| Guo, X | 1 |
| Camargo, F | 1 |
| Erickson, RP | 1 |
| Garver, WS | 1 |
| Hossain, GS | 1 |
| Carbone, PN | 1 |
| Heidenreich, RA | 1 |
| Blanchard, J | 1 |
| Maeda, T | 1 |
| Maruyama, I | 1 |
| Metoki, T | 1 |
| Sawada, H | 1 |
| Dezawa, M | 1 |
| Rossi, GP | 1 |
| Cavallin, M | 1 |
| Belloni, AS | 1 |
| Mazzocchi, G | 1 |
| Nussdorfer, GG | 1 |
| Pessina, AC | 1 |
| Sartore, S | 1 |
| Palmieri, V | 1 |
| Devereux, RB | 1 |
| Alvarez, BV | 1 |
| Ennis, IL | 1 |
| De Hurtado, MC | 1 |
| Cingolani, HE | 1 |
| Kryzhanovskiĭ, GN | 2 |
| Karpova, MN | 2 |
| Abramova, EM | 2 |
| Abrosimov, IIu | 2 |
| Pankov, OIu | 1 |
| Waters, D | 1 |
| Lespérance, J | 1 |
| Belis, JA | 1 |
| Curley, RM | 1 |
| Wagner, CH | 1 |
| Murty, VN | 1 |
| Winter, SJ | 1 |
| Rohner, TJ | 1 |
| Poloński, L | 1 |
| Polońska, A | 1 |
| Tendera, M | 1 |
| Wodniecki, J | 1 |
| Krzywiecki, A | 1 |
| Rivera, JM | 1 |
| Cosín, J | 1 |
| Hernándiz, A | 1 |
| Andrés, F | 1 |
| Solaz, J | 1 |
| Momomura, S | 1 |
| Serizawa, T | 1 |
| Ikenouchi, H | 1 |
| Sugimoto, T | 1 |
| Iizuka, M | 1 |
| Crosson, CE | 1 |
| Willis, JA | 1 |
| Potter, DE | 1 |
| Herrera, DG | 1 |
| Robertson, HA | 1 |
| McNally, PG | 1 |
| Baker, F | 1 |
| Mistry, N | 1 |
| Walls, J | 1 |
| Feehally, J | 1 |
| Yamamoto, F | 1 |
| Manning, AS | 1 |
| Crome, R | 1 |
| Kidooka, M | 1 |
| Matsuda, M | 1 |
| Handa, J | 1 |
| Sato, T | 1 |
| Nara, Y | 1 |
| Note, S | 1 |
| Yamori, Y | 1 |
| Tominaga, M | 1 |
| Kawai, C | 1 |
| Seuter, F | 1 |
| Togari, A | 1 |
| Arai, M | 1 |
| Shamoto, T | 1 |
| Matsumoto, S | 1 |
| Nagatsu, T | 1 |
| Wagner, JA | 1 |
| Reynolds, IJ | 1 |
| Weisman, HF | 1 |
| Dudeck, P | 1 |
| Weisfeldt, ML | 1 |
| Snyder, SH | 1 |
| Schranz, D | 1 |
| Huth, RG | 1 |
| Stopfkuchen, H | 1 |
| Jüngst, BK | 1 |
| Myers, AK | 1 |
| Forman, G | 1 |
| Torres Duarte, AP | 1 |
| Penhos, J | 1 |
| Ramwell, P | 1 |
| Griffeth, JK | 1 |
| Gallagher, TJ | 1 |
| Packer, DL | 1 |
| Priori, SG | 1 |
| Zuanetti, G | 1 |
| Schwartz, PJ | 1 |
| Hugenholtz, PG | 1 |
| Lichtlen, P | 1 |
| van der Giessen, W | 1 |
| Becker, AE | 1 |
| Nayler, WG | 1 |
| Fleckenstein, A | 1 |
| Hülsmann, WC | 1 |
| Ortega, MP | 1 |
| Sunkel, C | 1 |
| Priego, JG | 1 |
| Statkow, PR | 1 |
| Okasora, T | 1 |
| Bywater, RA | 1 |
| Taylor, GS | 1 |
| Satoh, K | 1 |
| Kawada, M | 1 |
| Wada, Y | 1 |
| Taira, N | 1 |
| Reimer, KA | 1 |
| Jennings, RB | 1 |
| Parmley, WW | 1 |
| Blumlein, S | 1 |
| Sievers, R | 1 |
| Zabramski, J | 1 |
| Spetzler, RF | 1 |
| Bonstelle, C | 1 |
| Bichler, KH | 1 |
| Strohmaier, WL | 1 |
| Schanz, F | 1 |
| Nelde, HJ | 1 |
| Gaiser, I | 1 |
| Schulze, E | 1 |
| Schreiber, M | 1 |
| Fukunami, M | 1 |
| Philips, JB | 1 |
| Lyrene, RK | 1 |
| Leslie, GI | 1 |
| McDevitt, M | 1 |
| Cassady, G | 1 |
| Yokoyama, M | 2 |
| Sakamoto, S | 2 |
| Kawashima, S | 1 |
| Okada, T | 1 |
| Fukuzaki, H | 2 |
| Kusui, A | 1 |
| Akita, H | 1 |
| Maekawa, K | 1 |
| Alps, BJ | 1 |
| Calder, C | 1 |
| Wilson, A | 1 |
| Koshino, T | 1 |
| Fujimura, M | 1 |
| Minami, S | 1 |
| Nishioka, S | 1 |
| Okafuji, K | 1 |
| Kanamori, K | 1 |
| Matsuda, T | 1 |
| Ishizaki, T | 1 |
| Saga, T | 1 |
| Miyabo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study[NCT06098300] | 30 participants (Anticipated) | Observational | 2023-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for nifedipine and Disease Models, Animal
| Article | Year |
|---|---|
[Cause of retinitis pigmentosa and new therapeutics under development].
Topics: Animals; c-Mer Tyrosine Kinase; Carrier Proteins; cis-trans-Isomerases; Cyclic Nucleotide Phosphodie | 2011 |
[New drug therapy for retinal degeneration].
Topics: Animals; Calcium Channel Blockers; Dark Adaptation; Disease Models, Animal; Humans; Mice; Mutation; | 2008 |
[Role of apoptosis in the kidney after reperfusion].
Topics: Animals; Apoptosis; Bepridil; Calcium Channel Blockers; Disease Models, Animal; Fendiline; Humans; K | 2008 |
Calcium antagonists, cerebral ischemia and vasospasm.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Cats; Cerebral Arteries; Cerebrovascular Circulat | 1984 |
High-altitude pulmonary edema: current concepts.
Topics: Acclimatization; Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disea | 1996 |
Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model.
Topics: Age Factors; Animals; Anticonvulsants; Calcium Channel Blockers; Cyclosporine; Dental Plaque; Diseas | 1996 |
Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension.
Topics: Animals; Blood Coagulation; Calcium Channel Blockers; Cyclic AMP; Cyclic GMP; Disease Models, Animal | 1995 |
Nifedipine-induced gingival overgrowth in rats: brief review and experimental study.
Topics: Analysis of Variance; Animals; Body Weight; Calcium Channel Blockers; Disease Models, Animal; Dose-R | 1998 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers.
Topics: Animals; Calcium Channel Blockers; Coronary Artery Disease; Disease Models, Animal; Heart Transplant | 1992 |
On a possible role for calcium antagonists in atherosclerosis. A personal view.
Topics: Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Dis | 1986 |
Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction.
Topics: Animals; Calcium Channel Blockers; Collateral Circulation; Coronary Circulation; Coronary Disease; D | 1985 |
Modification of experimental atherosclerosis by calcium-channel blockers.
Topics: Animals; Aorta; Arteriosclerosis; Calcium; Calcium Channel Blockers; Child; Diet, Atherogenic; Dilti | 1985 |
2 trials available for nifedipine and Disease Models, Animal
| Article | Year |
|---|---|
Calcium antagonists, cerebral ischemia and vasospasm.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Cats; Cerebral Arteries; Cerebrovascular Circulat | 1984 |
On a possible role for calcium antagonists in atherosclerosis. A personal view.
Topics: Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Dis | 1986 |
204 other studies available for nifedipine and Disease Models, Animal
| Article | Year |
|---|---|
4-Phenyl-4H-pyrans as IK(Ca) channel blockers.
Topics: Animals; Blood Pressure; Brain; Brain Infarction; Brain Injuries; Disease Models, Animal; Dose-Respo | 2003 |
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.
Topics: Acetamides; Analgesics; Animals; Behavior, Animal; Calcium Channel Blockers; Calcium Channels, N-Typ | 2012 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication.
Topics: Angiotensin II; Animals; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Disease Models, Animal; Folic | 2022 |
Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication.
Topics: Angiotensin II; Animals; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Disease Models, Animal; Folic | 2022 |
Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication.
Topics: Angiotensin II; Animals; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Disease Models, Animal; Folic | 2022 |
Combination of folic acid with nifedipine is completely effective in attenuating aortic aneurysm formation as a novel oral medication.
Topics: Angiotensin II; Animals; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Disease Models, Animal; Folic | 2022 |
Nifedipine Ameliorates Cellular Differentiation Defects of Smn-Deficient Motor Neurons and Enhances Neuromuscular Transmission in SMA Mice.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Mice; Motor Neurons; Muscular Atrophy, Spinal | 2023 |
Nifedipine attenuates alveolar bone destruction and improves trabecular microarchitectures in mice with experimental periodontitis.
Topics: Alveolar Bone Loss; Animals; Disease Models, Animal; Mice; Nifedipine; Periodontitis; Porphyromonas | 2023 |
Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Chlorocebus aethiops; Diseas | 2019 |
Development and evaluation of next-generation cardiotoxicity assay based on embryonic stem cell-derived cardiomyocytes.
Topics: Animals; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Doxorubicin; | 2020 |
Nifedipine Exacerbates Lipogenesis in the Kidney via KIM-1, CD36, and SREBP Upregulation: Implications from an Animal Model for Human Study.
Topics: Animals; CD36 Antigens; Diet, High-Fat; Disease Models, Animal; Doxorubicin; Female; Gene Expression | 2020 |
Engineering of Nanospheres Dispersed Microneedle System for Antihypertensive Action.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Cadmium Chloride; Chemi | 2020 |
Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Doxorubicin; Heart; Heart | 2021 |
Combination of aqueous extracts of Curcuma longa (turmeric) and some calcium channel blockers synergistically improves CCl4-induced nephrotoxicity in albino rats.
Topics: Acute Kidney Injury; Amlodipine; Animals; Antioxidants; Calcium Channel Blockers; Carbon Tetrachlori | 2020 |
Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment.
Topics: Administration, Ophthalmic; Animals; Calcium Channel Blockers; Chemistry, Pharmaceutical; Delayed-Ac | 2021 |
Clarification of serotonin-induced effects in peripheral artery disease observed through the femoral artery response in models of diabetes and vascular occlusion: The role of calcium ions.
Topics: Animals; Calcium; Diabetes Complications; Disease Models, Animal; Femoral Artery; Nifedipine; Ouabai | 2017 |
Anticonvulsant effects of antiaris toxicaria aqueous extract: investigation using animal models of temporal lobe epilepsy.
Topics: Animals; Antiaris; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Drug Administra | 2017 |
Synaptic potentiation mediated by L-type voltage-dependent calcium channels mediates the antidepressive effects of lateral habenula stimulation.
Topics: Action Potentials; Animals; Astrocytes; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; | 2017 |
Antidepressants Rescue Stress-Induced Disruption of Synaptic Plasticity via Serotonin Transporter-Independent Inhibition of L-Type Calcium Channels.
Topics: Age Factors; Animals; Antidepressive Agents; Cadmium Chloride; Calcium Channel Blockers; Calcium Cha | 2018 |
Axon Initial Segment Structural Plasticity is Involved in Seizure Susceptibility in a Rat Model of Cortical Dysplasia.
Topics: Animals; Axon Initial Segment; Axons; Disease Models, Animal; Disease Susceptibility; Electroencepha | 2018 |
Postnatal developmental changes in the sensitivity of L-type Ca
Topics: Animals; Bradycardia; Calcium Channel Blockers; Calcium Channels, L-Type; Diltiazem; Disease Models, | 2018 |
8-Br-cADPR, a TRPM2 ion channel antagonist, inhibits renal ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Blood Urea Nitrogen; Calcium Channel Blockers; Catalas | 2019 |
Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation.
Topics: Aminopropionitrile; Angiotensin II; Animals; Antigens, Differentiation; Antioxidants; Aortic Aneurys | 2018 |
A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dis | 2019 |
T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction.
Topics: Acetylcholine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type | 2014 |
Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Bl | 2014 |
Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride-induced hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Arterial Pressure; Biomarkers; Disease Models, Anima | 2014 |
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Calcium Channel Blockers; Carbon Tetrachloride; Cytoprotection; D | 2014 |
Alterations of voltage-dependent calcium channel currents in basilar artery smooth muscle cells at early stage of subarachnoid hemorrhage in a rabbit model.
Topics: Animals; Basilar Artery; Blood Pressure; Body Weight; Brain; Calcium Channels; Calcium Channels, L-T | 2014 |
Nifedipine-sensitive blood pressure component in hypertensive models characterized by high activity of either sympathetic nervous system or renin-angiotensin system.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Hypertension; Male; Nifed | 2014 |
Effect of nifedipine on hippocampal neuron number in penicillin-induced epileptic rats.
Topics: Animals; Calcium Channel Blockers; Cell Survival; Cerebral Cortex; Disease Models, Animal; Epilepsy; | 2014 |
Nifedipine-induced histological changes in the parotid glands of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Body Weight; Disease Models, Animal; Hypertension; Male; Nifedipin | 2014 |
Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats.
Topics: Animals; Brain Diseases; Calcium Channel Blockers; Cholinesterase Inhibitors; Disease Models, Animal | 2014 |
Local Inflammation Alters MMP-2 and MMP-9 Gelatinase Expression Associated with the Severity of Nifedipine-Induced Gingival Overgrowth: a Rat Model Study.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Gingival | 2015 |
Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats.
Topics: Animals; Calcium; Calcium Channels; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Endotheli | 2015 |
A protective role of Nox1/NADPH oxidase in a mouse model with hypoxia-induced bradycardia.
Topics: Action Potentials; Animals; Bradycardia; Calcium Channel Blockers; Disease Models, Animal; Electroca | 2015 |
Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cytoprotection; Disease | 2015 |
The Wnt11 Signaling Pathway in Potential Cellular EMT and Osteochondral Differentiation Progression in Nephrolithiasis Formation.
Topics: Animals; Biomarkers; Blotting, Western; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; | 2015 |
Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus.
Topics: Animals; Attention; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Calcium Channels; Capillar | 2016 |
Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Ca | 2016 |
A Novel Small Molecule Modulator of Amyloid Pathology.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antipsyc | 2016 |
Comparison of anti-anginal effect of cilnidipine with those of nicardipine and nifedipine in the vasopressin-induced angina model of rats.
Topics: Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calciu | 2016 |
Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
Topics: Adult; Animals; Antiprotozoal Agents; Chagas Disease; Chronic Disease; Clofazimine; Cysteine Endopep | 2016 |
Pilot Trial of Intravenous Lipid Emulsion Treatment for Severe Nifedipine-Induced Shock.
Topics: Animals; Blood Glucose; Blood Pressure; Bradycardia; Calcium Channel Blockers; Dihydropyridines; Dis | 2016 |
Topical application of nitrosonifedipine, a novel radical scavenger, ameliorates ischemic skin flap necrosis in a mouse model.
Topics: Administration, Topical; Animals; Antioxidants; Blotting, Western; Disease Models, Animal; Graft Sur | 2017 |
Nimodipine is more effective than nifedipine in attenuating morphine tolerance on chronic co-administration in the rat tail-flick test.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Disease Models, Animal; Dos | 2008 |
Urotheliogenic modulation of intrinsic activity in spinal cord-transected rat bladders: role of mucosal muscarinic receptors.
Topics: Animals; Arecoline; Calcium Channel Blockers; Disease Models, Animal; Female; Mucous Membrane; Musca | 2008 |
Late blood pressure reduction in SHR subjected to transient captopril treatment in youth: possible mechanisms.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Press | 2008 |
Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Agonists; Calcium Channel | 2009 |
CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Arterioles; Calcium Channel Blockers; Disease Models, Animal; Endothelin A Receptor Antagon | 2009 |
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Collagen; Disease Models, Animal; Fibros | 2009 |
Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis.
Topics: Animals; Biomarkers; Calcium Channel Blockers; Cardiovirus Infections; Collagen Type I; Disease Mode | 2009 |
Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V | 2009 |
Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Arginine; Biophysical Phenomena; Biophysics; Calcium Channel | 2009 |
Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.
Topics: Animals; Blood Pressure; Bradykinin; Calcium Channel Blockers; Cyclooxygenase Inhibitors; Cytochrome | 2010 |
Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension.
Topics: Age Factors; Aging; Animals; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Block | 2009 |
Increased colonic motility in a rat model of irritable bowel syndrome is associated with up-regulation of L-type calcium channels in colonic smooth muscle cells.
Topics: Acetylcholine; Analysis of Variance; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Co | 2010 |
Upregulation of L-type Ca(v)1 channels in the development of psychological dependence.
Topics: Animals; Brain; Brain Chemistry; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signali | 2010 |
[Antihypertrophic effect of dihydropyridines calcium channel blockers is dependent on their potential of blocking N-type calcium channel].
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Cardiomegaly; Dihydropyridi | 2010 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
Effect of nifedipine on gingival enlargement and periodontal breakdown in ligature-induced periodontitis in rats.
Topics: Alveolar Bone Loss; Alveolar Process; Animals; Calcium Channel Blockers; Connective Tissue; Cotton F | 2010 |
Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.
Topics: Algorithms; Animals; Blood Pressure; Calcium Channel Blockers; Calcium-Calmodulin-Dependent Protein | 2010 |
Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Topics: Adipocytes; Adipogenesis; Adiponectin; Adipose Tissue, White; Animals; Blood Glucose; Calcium Channe | 2011 |
Calcium/calmodulin-dependent kinase II facilitated GluR6 subunit serine phosphorylation through GluR6-PSD95-CaMKII signaling module assembly in cerebral ischemia injury.
Topics: Analysis of Variance; Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dis | 2010 |
Marfan syndrome decreases Ca2+ wave frequency and vasoconstriction in murine mesenteric resistance arteries without changing underlying mechanisms.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Signaling; Cations, Divalent; Disease Models, An | 2011 |
Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dia | 2010 |
Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis.
Topics: Animals; Blood-Aqueous Barrier; Calcium Channel Blockers; Cell Adhesion; Chemokine CCL2; Diltiazem; | 2010 |
AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency.
Topics: Animals; Calcium Channel Blockers; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Cycli | 2011 |
TRPM3 is a nociceptor channel involved in the detection of noxious heat.
Topics: Acrylamides; Animals; Behavior, Animal; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Calc | 2011 |
Nifedipine increases energy expenditure by increasing PGC-1α expression in skeletal muscle.
Topics: Adipose Tissue; Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationshi | 2011 |
Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.
Topics: Alanine Transaminase; Animals; Bezafibrate; Calcium Channel Blockers; Choline Deficiency; Diet; Dise | 2012 |
L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Block | 2012 |
Cardiac tissue slices with prolonged survival for in vitro drug safety screening.
Topics: 4-Aminopyridine; Action Potentials; Animal Testing Alternatives; Animals; Animals, Laboratory; Anti- | 2012 |
Calcium channel blockers reduce the effects of cigarette smoking on peripheral nerve ischemia/reperfusion injury.
Topics: Animals; Calcium Channel Blockers; Cotinine; Disease Models, Animal; Male; Nifedipine; Rats; Rats, W | 2013 |
T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice.
Topics: Animals; Azoles; Base Sequence; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels, L-Type | 2012 |
Anti-psychotic and sedative effect of calcium channel blockers in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Disease Models, Ani | 2010 |
Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB.
Topics: Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disease Models, Animal | 2012 |
A critical role for protein tyrosine phosphatase nonreceptor type 5 in determining individual susceptibility to develop stress-related cognitive and morphological changes.
Topics: Aggression; Analysis of Variance; Animals; Biophysics; Brain; Calcium Channel Blockers; Cell Line, T | 2012 |
Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma.
Topics: Animals; Arginine; Blood Circulation; Blood Flow Velocity; Calcium Channel Blockers; Disease Models, | 2012 |
Anticonvulsant and antiarrhythmic effects of nifedipine in rats prone to audiogenic seizures.
Topics: Acoustic Stimulation; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmias, Cardiac; Diseas | 2012 |
The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels.
Topics: Amides; Animals; Calcium Channels, L-Type; Carbachol; Cholinergic Agonists; Disease Models, Animal; | 2012 |
Antagonism of L-type Ca(v) channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-Choice Serial Reaction-Time Task.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Calcium Channel Blockers; | 2013 |
Cerebrovascular alterations in pressure and protein kinase C-mediated constriction in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Disease Models, Animal | 2002 |
Effect of melatonin and nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats.
Topics: 3-Hydroxybutyric Acid; Animals; Antioxidants; Blood; Brain; Calcium Channel Blockers; Disease Models | 2002 |
Life span of ventricular fibrillation frequencies.
Topics: Action Potentials; Algorithms; Animals; Biological Clocks; Calcium Channel Blockers; Calcium Channel | 2002 |
Nifedipine induces gingival epithelial hyperplasia in rats through inhibition of apoptosis.
Topics: Animals; Antimetabolites; Apoptosis; Bromodeoxyuridine; Calcium Channel Blockers; Cell Division; Cel | 2002 |
The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angioplasty, Balloon, Coronary; Animals; Aorta, Thoracic; | 2002 |
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Ch | 2003 |
Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models | 2003 |
Expression of the nuclear factor-kappaB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke.
Topics: Animals; Aorta, Thoracic; Biomarkers; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Di | 2003 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
Low expression of rhodopsin kinase in pineal gland in Royal College of Surgeons rat.
Topics: Animals; Arrestin; Blotting, Western; Calcium Channel Blockers; Calcium-Binding Proteins; Disease Mo | 2003 |
[Effect of stress on calcium homeostasis in muscular tissues].
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; Homeos | 2003 |
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcium Channel B | 2004 |
[Effects of Ca2+ antagonist on cardiomyocytic apoptosis after experimental myocardial infarction].
Topics: Animals; Apoptosis; Calcium Channel Blockers; Disease Models, Animal; fas Receptor; Immunohistochemi | 2004 |
Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interaction | 2004 |
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Topics: Adenosine Triphosphate; Amides; Animals; Benzophenones; Blood Pressure; Cyclic S-Oxides; Cyclobutane | 2004 |
Altered vulnerability to kainate excitotoxicity of transgenic-Cu/Zn SOD1 neurones.
Topics: Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Asparagine; Calcium Channel Blockers; | 2004 |
Emergence of a R-type Ca2+ channel (CaV 2.3) contributes to cerebral artery constriction after subarachnoid hemorrhage.
Topics: Animals; Blood; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, R-Typ | 2005 |
[Dynamics of calcium intake in the brain tissue in hypercholesterolemia].
Topics: Animals; Brain; Calcium; Cholesterol; Disease Models, Animal; Hypercholesterolemia; Nifedipine; Rats | 2004 |
The responses to manipulation of extracellular and intracellular calcium are altered in the streptozotocin-diabetic rat colon and ileum.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2005 |
Increased seizure susceptibility of the hippocampus compared with the neocortex of the immature mouse brain in vitro.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Calcium Channel Blockers | 2005 |
Ethanol physical dependence is accompanied by up-regulated expression of L-type high voltage-gated calcium channel alpha1 subunits in mouse brain.
Topics: Administration, Inhalation; Alcoholism; Animals; Brain; Calcium Channel Blockers; Calcium Channels, | 2005 |
[Effects of nifedipine controlled release on blood pressure and heart rate of spontaneously hypertensive rats. Comparison with nifedipine standard and with amlodipine].
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2005 |
Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Cyclosporine; Disease Models, Animal; Immunohistochem | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Apoptosis; Blotting, Western; Calcium | 2005 |
Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2005 |
Hypoxia induces hypersensitivity and hyperreactivity to thromboxane receptor agonist in neonatal pulmonary arterial myocytes.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Animals, Newborn; Calci | 2006 |
Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Composition; Body Constitution; Body Weight; | 1993 |
Anti-hypertension effects of traditional Chinese medicine ju-ling-tang on renal hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biopsy; Coronary Vessels; Disease Models, Animal; Drugs, Chinese H | 2005 |
Effects of verapamil and nifedipine on different parameters in lipopolysaccharide-induced septic shock.
Topics: Animals; Calcium Channel Blockers; Carotid Arteries; Catalase; Disease Models, Animal; Interleukin-1 | 2006 |
Ambient particulate matter affects cardiac recovery in a Langendorff ischemia model.
Topics: Air Pollutants; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Coronary Circulation; | 2006 |
Nifedipine suppresses self-injurious behaviors in animals.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2007 |
Effects of benidipine in a rat model for experimental angina.
Topics: Amlodipine; Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Di | 2006 |
Effects of renovascular hypertension on reproductive function in male rats.
Topics: Animals; Disease Models, Animal; Female; Follicle Stimulating Hormone; Hypertension, Renovascular; I | 2007 |
Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Disease Models, Animal; Drug Evaluation, Precl | 2008 |
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Antineoplasti | 2007 |
Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine.
Topics: Animals; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Cognition; Cognition Disorder | 2008 |
Inhibition of experimental abdominal aortic aneurysm progression by nifedipine.
Topics: Animals; Aortic Aneurysm, Abdominal; Blood Pressure; Blotting, Western; Calcium Channel Blockers; Ce | 2008 |
Nifedipine inhibits the progression of an experimentally induced cerebral aneurysm in rats with associated down-regulation of NF-kappa B transcriptional activity.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Dis | 2008 |
Adrenalectomy potentiates the anti-inflammatory activity of a calcium channel blocker.
Topics: Acute Disease; Adrenalectomy; Animals; Anti-Inflammatory Agents; Calcium Channel Blockers; Carrageen | 2007 |
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2008 |
Particulate contamination: a potential hazard of cardioplegia.
Topics: Animals; Disease Models, Animal; Dogs; Drug Contamination; Heart Arrest, Induced; Humans; Male; Nife | 1983 |
Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dog | 1984 |
Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies.
Topics: Acute Kidney Injury; Animals; Calcium; Calcium Channel Blockers; Cytoplasm; Disease Models, Animal; | 1984 |
Cardioprotection with calcium antagonists by suppression of early ischaemia and reperfusion-induced arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Coronary Disease; Disease Models, | 1983 |
Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cathepsin D; Cathepsins; Cats; Disease M | 1984 |
Evaluation of cardiac anoxia and ischemia models in the rat using calcium antagonists.
Topics: Adenine Nucleotides; Animals; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Corona | 1984 |
In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy.
Topics: Animals; Benzazepines; Calcium; Chickens; Creatine Kinase; Diltiazem; Disease Models, Animal; Female | 1984 |
Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs.
Topics: Animals; Blood Platelets; Calcium Channel Blockers; Dipyridamole; Disease Models, Animal; Dogs; Fibr | 1983 |
Failure of nifedipine therapy to reduce myocardial infarct size in the baboon.
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dru | 1982 |
Evidence that the increased calcium sensitivity of resistance vessels in spontaneously hypertensive rats is an intrinsic defect of their vascular smooth muscle.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium; Disease Models, Animal; Felodipine; Hyper | 1981 |
Improved performance of ischemic canine myocardium in response to nifedipine and diltiazem.
Topics: Animals; Benzazepines; Coronary Circulation; Coronary Disease; Diltiazem; Disease Models, Animal; Do | 1980 |
Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1994 |
Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Bradycardia; | 1995 |
Increased sensitivity to inhibition by nifedipine of responses of the mesenteric artery bed of the SHRSP to noradrenaline is not dependent on alpha 1-adrenoceptor subtypes.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; An | 1995 |
Impairement of endothelium-dependent relaxation in chronic two-kidney, one clip hypertensive rats.
Topics: Acetylcholine; Animals; Constriction; Disease Models, Animal; Hypertension; In Vitro Techniques; Mal | 1994 |
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Topics: Adult; Aged; Aged, 80 and over; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cells, | 1994 |
Effects of beta-blockers and Ca(2+)-antagonists on the response of the isolated working rat heart to adrenergic stimulants after cardioplegic arrest.
Topics: Adenine Nucleotides; Animals; Cardiac Output; Cardiotonic Agents; Disease Models, Animal; Dobutamine | 1993 |
Nifedipine-induced gingival overgrowth in the presence or absence of gingival inflammation in rats.
Topics: Analysis of Variance; Animals; Dental Plaque; Dental Plaque Index; Disease Models, Animal; Gingival | 1993 |
Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats.
Topics: Angina Pectoris; Animals; Disease Models, Animal; Electrocardiography; Injections, Intravenous; Isop | 1993 |
The influence of nifedipine on microvascular vein graft intimal thickening.
Topics: Animals; Capillaries; Disease Models, Animal; Drug Evaluation, Preclinical; Graft Occlusion, Vascula | 1993 |
Effects of a new calcium antagonist, CD-832, on experimental coronary artery spasm in miniature pigs.
Topics: Animals; Calcium Channel Blockers; Coronary Vasospasm; Disease Models, Animal; Histamine; Infusions, | 1993 |
[Effect of palonidipine hydrochloride (TC-81), a new dihydropyridine derivative, on various myocardial ischemic models].
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Circulation; Coronary Vessels; Dihydrop | 1993 |
The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats.
Topics: Acute Disease; Animals; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Ven | 1993 |
Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Blood Pressure; Bundle of His; Calcium C | 1995 |
Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.
Topics: Acetylcholine; Angina Pectoris; Animals; Arginine Vasopressin; Calcium Channel Blockers; Coronary Ve | 1995 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase.
Topics: Animals; Arginine; Colitis; Colon; Dexamethasone; Dilatation; Disease Models, Animal; Enzyme Inducti | 1996 |
Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Bronchodilator Agents; Calcium; Calcium Channel Block | 1996 |
The potential synergistic effect of calcium channel blockers and alpha-tocopherol on gastric mucosal injury induced by ischaemia-reperfusion.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Dose-Res | 1996 |
Effects of nifedipine and platelet activating factor antagonist (BN 52021) in glycerol-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Administration, Oral; Analysis of Variance; Animals; Creatinine; Disease Models | 1996 |
Effect of antiepileptic drugs and calcium channel blocker on hyperthermic seizures in rats: animal model for hot water epilepsy.
Topics: Animals; Anticonvulsants; Body Temperature; Calcium Channel Blockers; Disease Models, Animal; Electr | 1996 |
Increased risk in esophageal obstruction with slow-release medications.
Topics: Aged; Animals; Carcinoma, Squamous Cell; Delayed-Action Preparations; Disease Models, Animal; Drug S | 1997 |
Antihypertensive effect of some oxazolo[3,2-a]pyridines, thiazolo[3,2-a]pyridines and pyrido[2,1-b]oxazines in conscious spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; | 1997 |
A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Chrom | 1997 |
Hepatic ischemia-reperfusion injury modification during liver surgery in rats: pretreatment with nifedipine or misoprostol.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Hepatectomy; Liver; Liver Diseases; Liver | 1995 |
Microvascular permeability with sulfonylureas in normal and diabetic hamsters.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Capillary Permeability; Cricetinae; Dextrans; D | 1997 |
The effect of electroconvulsive treatment on thermal hyperalgesia and mechanical allodynia in a rat model of peripheral neuropathy.
Topics: Animals; Calcium Channels; Disease Models, Animal; Electroshock; Hot Temperature; Hyperalgesia; Male | 1998 |
Preventive strategies in endothelin-induced renal failure.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, No | 1998 |
Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Blotting, Southern; Brain; Calcium Channel Blockers; Cardiovascular | 1999 |
The effects of short-term nifedipine treatment on responsiveness of aortic rings of cadmium-hypertensive rats.
Topics: Acetylcholine; Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Cadmium Chloride; Calcium C | 1999 |
Antihypertensive effects of Dorstenia psilurus extract in fructose-fed hyperinsulinemic, hypertensive rats.
Topics: Africa; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cholesterol; Creatinine; Di | 2001 |
Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Alprostadil; Animals; Antihypert | 2001 |
Does nifedipine aggravate cyclosporin--induced gingival overgrowth? An experiment in rats.
Topics: Animals; Calcium Channel Blockers; Cyclosporine; Dental Enamel; Dentin; Disease Models, Animal; Dose | 2001 |
Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Disease Models, Animal; Heart Failure; Male; Microsco | 2001 |
Enhanced calcium influx in hippocampal CA3 neurons of spontaneously epileptic rats.
Topics: Animals; Calcium; Calcium Channels; Dentate Gyrus; Disease Models, Animal; Dose-Response Relationshi | 2001 |
[Experimental study on effect of altitude xishi capsule in treating oleic acid induced lung injury in acute hypoxia rats].
Topics: Animals; Dexamethasone; Disease Models, Animal; Drug Combinations; Hypoxia; Male; Nifedipine; Oleic | 1998 |
Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Anticholesteremic Agents; Ataxia; beta-Cyclodextrins; Bl | 2001 |
Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Caspase 1; Caspase 2; Caspases; Crystallins; D | 2002 |
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Geneticall | 2002 |
Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Disease Mo | 2002 |
[The antiepileptic effects of sodium valproate and the calcium antagonist riodipine when used jointly in a model of focal penicillin-induced epileptic activity].
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synerg | 1992 |
[The antiepileptic effects of sodium valproate and the calcium antagonist riodipine when used jointly in a model of generalized korazol-induced epileptic activity].
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ev | 1992 |
Neurogenic function of the diabetic rat bladder: alteration by calcium channel effectors.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
[Verapamil and nifedipine limit hemodynamic changes in pulmonary circulation in rats with hypoxia].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Depression, Chemical; Disease Models, Animal; Hype | 1991 |
[The cardioprotective action of nifedipine during short-term transient ischemia].
Topics: Animals; Coronary Disease; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Female; Heart | 1991 |
Effects of nifedipine on diastolic abnormalities in low-flow and pacing-induced ischemia in isolated rat hearts.
Topics: Angina Pectoris; Animals; Blood Pressure; Cardiac Pacing, Artificial; Coronary Circulation; Coronary | 1991 |
Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Female; Isch | 1990 |
N-methyl-D-aspartate receptors mediate activation of the c-fos proto-oncogene in a model of brain injury.
Topics: Animals; Anticonvulsants; Atropine; Brain; Brain Injuries; Dibenzocycloheptenes; Disease Models, Ani | 1990 |
Effect of nifedipine on renal haemodynamics in an animal model of cyclosporin A nephrotoxicity.
Topics: Animals; Cyclosporins; Disease Models, Animal; Female; Glomerular Filtration Rate; Hemodynamics; Kid | 1990 |
Calcium antagonists and myocardial protection: a comparative study of the functional, metabolic and electrical consequences of verapamil and nifedipine as additives to the St. Thomas' cardioplegic solution.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardiopulmonary Bypass; Disease Models, Anim | 1985 |
Effect of calcium antagonist and agonist on free fatty acid liberation in the ischemic brain of rats.
Topics: Animals; Arachidonic Acids; Brain; Brain Ischemia; Disease Models, Animal; Fatty Acids, Nonesterifie | 1987 |
Effect of calcium antagonists on hypertension and diabetes in new hypertensive diabetic models.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diltiazem; Disea | 1987 |
[Treatment of cardiomyopathy using Ca blockers].
Topics: Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cricetinae | 1989 |
[Pharmacologic inhibition of experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; | 1989 |
Elevation of blood pressure in young rats fed a low calcium diet. Effects of nifedipine and captopril.
Topics: Animals; Blood Pressure; Body Weight; Calcium; Captopril; Diet; Disease Models, Animal; Heart Rate; | 1989 |
Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain.
Topics: Animals; Brain; Brain Chemistry; Calcium; Calcium Channels; Cardiomyopathy, Hypertrophic; Cricetinae | 1986 |
The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet.
Topics: Animals; Animals, Newborn; Aspirin; Disease Models, Animal; Drug Combinations; Drug Evaluation, Prec | 1988 |
Comparison of verapamil and nifedipine in thrombosis models.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Collagen; Disease Models, Animal; Epinephrine; Male; N | 1986 |
Hemodynamic effects of nifedipine in a canine model of acid aspiration.
Topics: Animals; Disease Models, Animal; Dogs; Hemodynamics; Hydrochloric Acid; Nifedipine; Pneumonia, Aspir | 1988 |
Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: effect of nifedipine.
Topics: Acute Disease; Animals; Cardiac Pacing, Artificial; Cats; Coronary Disease; Disease Models, Animal; | 1988 |
The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice.
Topics: Animals; Calcium Channel Blockers; Collagen; Dihydropyridines; Diltiazem; Disease Models, Animal; Do | 1987 |
Projections of enteric motor neurons in the mouse distal colon.
Topics: Animals; Apamin; Atropine; Colon; Disease Models, Animal; Electric Stimulation; Evoked Potentials; H | 1986 |
Nicardipine releases sustained coronary arterial constriction induced by acetylcholine in the rhesus monkey.
Topics: Acetylcholine; Animals; Coronary Circulation; Coronary Vasospasm; Coronary Vessels; Disease Models, | 1985 |
Chronic cerebral vasospasm: effect of calcium antagonists.
Topics: Animals; Cerebral Angiography; Chronic Disease; Disease Models, Animal; Dogs; Injections; Ischemic A | 1986 |
[Effect of calcium antagonists (nifedipine) on nephrocalcinosis and calcium excretion in the rat].
Topics: Animals; Calcium; Diet, Atherogenic; Disease Models, Animal; Hydrogen-Ion Concentration; Kidney; Kid | 1985 |
Temperature-dependency of nifedipine as a protective agent during cardioplegia in the rat.
Topics: Animals; Cardiopulmonary Bypass; Coronary Circulation; Creatine Kinase; Disease Models, Animal; Dose | 1985 |
Hemodynamic effects of nifedipine in normoxic and hypoxic newborn lambs.
Topics: Analysis of Variance; Animals; Animals, Newborn; Blood Gas Analysis; Blood Pressure; Disease Models, | 1985 |
Myocardial ischaemia produced by ergonovine-induced vasoconstriction during preexisting coronary stenosis: experimental conditions for the geometric theory.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Constriction, Pathologic; Coronary Circulation | 1985 |
Effects of nifedipine on coronary vasculature in canine models of dynamic and fixed coronary stenoses.
Topics: Animals; Coronary Circulation; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Dos | 1985 |
Nicardipine in models of myocardial infarction.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dogs; Electrocardiography; Heart Conducti | 1985 |
Effect of a Ca2+ antagonist, nifedipine, on the experimental asthma mediated mainly by slow reacting substance of anaphylaxis.
Topics: Airway Resistance; Animals; Asthma; Blood Pressure; Disease Models, Animal; Guinea Pigs; Immunizatio | 1985 |